Danish Medical Equipment Stock News

Buyback announcement and why it matters Netcompany Group (CPSE:NETC) has launched a share buyback programme of up to DKK 500 million, targeting a maximum of 3,700,000 shares, to reshape its capital structure and cover share based incentives. The programme, running no later than 30 January 2026 under EU Market Abuse Regulation, leaves Netcompany holding 1,735,556 treasury shares, equal to 3.7% of its share capital. See our latest analysis for Netcompany Group. Netcompany’s share price has been...

If you are wondering whether FLSmidth at a last close of kr.474.4 still offers value, you are not alone. The recent share performance has put its pricing firmly in the spotlight. The stock has posted returns of 6.6% over the last 7 days, 14.1% over the last 30 days, 5.4% year to date, 38.8% over 1 year, 83.1% over 3 years and 121.9% over 5 years, which naturally raises questions about what is already reflected in the price. Recent company updates and industry headlines have kept attention on...

If you are wondering whether Novo Nordisk shares still justify their current price, or if the recent buzz has pushed them too far, this article breaks down what the numbers say about value. The stock last closed at kr364.05, with returns of 11.9% over 7 days and 17.6% over 30 days, while the 1 year return stands at a 37.9% decline and the 5 year return at 86.3%. Recent coverage around Novo Nordisk has continued to focus on its role in the global pharmaceuticals and biotech sector, keeping...

ISS A/S has launched a new share buyback programme running until February 2026, authorising repurchases of up to DKK 3,000 million to reduce share capital and meet share-based incentive obligations. With treasury shares already amounting to 7.36% of its share capital, ISS is leaning heavily on buybacks as a capital return tool in a recurring-revenue services business. We will now examine how this sizeable share buyback plan shapes ISS’s investment narrative, especially its approach to...

Amidst a buoyant economic environment, the European markets have experienced notable gains, with the STOXX Europe 600 Index reaching new highs and major indices like Germany's DAX and France's CAC 40 posting significant increases. In this context of rising market performance, identifying undervalued stocks becomes crucial for investors seeking opportunities that may offer potential value relative to their intrinsic worth.

Over the past year, many TORM plc ( CPH:TRMD A ) insiders sold a significant stake in the company which may have piqued...

If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Firstly, we'll...

Recent coverage around Demant (CPSE:DEMANT) has centered on its push into AI-powered, lifestyle-focused hearing devices and a broad footprint across hearing aids, diagnostics, and audio communications, which appears to be supporting current investor interest. See our latest analysis for Demant. At a share price of DKK 223.8, Demant has seen short term momentum pick up, with a 1 month share price return of 3.4% and a year to date share price gain of 4.9%. However, the 1 year total shareholder...

If you are wondering whether Ørsted’s current share price reflects its true worth, this breakdown will help you see how the market’s view lines up with the underlying numbers. The stock last closed at DKK132.45, with returns of 8.3% over the past week, a 3.9% decline over the last 30 days, 3.5% year to date, and a 27.9% decline over the past year, alongside larger drawdowns over 3 and 5 years. These moves have played out as investors continue to reassess listed renewables companies and their...

In late 2025, Vestas announced a wave of new wind turbine orders totaling several gigawatts across Europe, North America, Asia, and Australia, including its first offshore contract in South Korea and multiple long-term service agreements extending up to 30 years. This broad mix of onshore and offshore projects, spread across developed and emerging wind markets, highlights how Vestas is deepening its global footprint while locking in recurring service revenue over the long term. We’ll now...

In late December 2025, Novo Nordisk secured FDA approval for and has now launched in the U.S. the Wegovy pill, the first once-daily oral GLP-1 therapy for chronic weight management and cardiovascular risk reduction, supported by Phase 3 data showing substantially greater weight loss than placebo when combined with diet and exercise. The pill’s broad rollout through major pharmacies, telehealth partners such as Ro, LifeMD, Weight Watchers, and platforms like GoodRx and NovoCare meaningfully...

The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But when you pick a company...

Genmab A/S recently reaffirmed its 2025 earnings guidance and decided to discontinue further clinical development of acasunlimab after evaluating its portfolio and the evolving competitive landscape. By reallocating resources toward late-stage assets such as EPKINLY (epcoritamab), petosemtamab and rinatabart sesutecan (Rina-S), Genmab is sharpening its late-stage antibody pipeline focus. We will now examine how concentrating capital on EPKINLY, petosemtamab and Rina-S could reshape Genmab’s...

Outlook for Vestas Wind Systems Shares After Recent Gains Vestas Wind Systems (CPSE:VWS) has quietly staged a strong comeback, with the stock up about 12% over the past month and roughly 40% in the past 3 months, drawing fresh investor attention. See our latest analysis for Vestas Wind Systems. That recent rebound comes after a tougher few years, with a 1 year total shareholder return of about 72% contrasting sharply with weaker 3 and 5 year total shareholder returns. This suggests momentum...

With a price-to-sales (or "P/S") ratio of 3.5x Zealand Pharma A/S ( CPH:ZEAL ) may be sending very bullish signals at...

The main aim of stock picking is to find the market-beating stocks. But the main game is to find enough winners to more...

With a price-to-earnings (or "P/E") ratio of 37.7x Ambu A/S ( CPH:AMBU B ) may be sending very bearish signals at the...

RIAS A/S ( CPH:RIAS B ) is reducing its dividend from last year's comparable payment to DKK26.00 on the 26th of...

Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...

Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...

Key Insights Using the 2 Stage Free Cash Flow to Equity, Pandora fair value estimate is kr.1,082 Current share price of...

Key Insights Given the large stake in the stock by institutions, Demant's stock price might be vulnerable to their...

Even if it's not a huge purchase, we think it was good to see that David Hojelsen, the Chief Technology Officer of...

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...